

119TH CONGRESS
1ST SESSION

S. 832

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

IN THE SENATE OF THE UNITED STATES

MARCH 4, 2025

Mr. TILLIS (for himself, Mr. BUDD, Mrs. BLACKBURN, Mr. DAINES, and Mr. LANKFORD) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Ensuring Pathways
5 to Innovative Cures Act of 2025” or the “EPIC Act of
6 2025”.

1 **SEC. 2. EQUALIZING THE NEGOTIATION PERIOD BETWEEN**
2 **SMALL-MOLECULE AND BIOLOGIC CAN-**
3 **DIDATES UNDER THE DRUG PRICE NEGOTIA-**
4 **TION PROGRAM.**

5 Section 1192(e)(1)(A)(ii) of the Social Security Act
6 (42 U.S.C. 1320f–1(e)(1)(A)(ii)) is amended—

7 (1) by striking “year, at least 7” and inserting
8 “year—

9 “(I) for initial price applicability
10 years 2026 and 2027, at least 7”; and

11 (2) by adding at the end the following:

12 “(II) for initial price applicability
13 year 2028 and each subsequent initial
14 price applicability year, at least 11
15 years will have elapsed since the date
16 of such approval; and”.

○